HANAROSTENT LowAxTM Duodenum/Pylorus(NNN): payments to doctors
Payments that named HANAROSTENT LowAxTM Duodenum/Pylorus(NNN) as the associated device or medical supply, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $664K
- Providers
- 71
- Transactions
- 124
- Average per transaction
- $5,358
The per-transaction average — $5,358 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 71 providers the average total is $9,357, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Olympus Corporation Of The Americas | $646,624 | 97.3% |
| Olympus America Inc. | $17,729 | 2.7% |